The results revealed that the expression differences of SLC16A1, ENO3 and LEPR were more obvious in the validation set, with SLC16A1 and LEPR being decreased in NAFLD, and ENO3 increased in NAFLD (Figure 8A,B). Here, SLC16A1 is linked to metabolic dysfunction-associated steatotic liver disease.